Psychedelic spray eased symptoms of treatment-resistant depression for several weeks

Published on: ⋄5 min read
Author: Valeriia Voronova, Editor at SOD Energy
Nasal psychedelic formulation as an investigational approach to treating treatment-resistant depression under medical supervision

Depression does not always respond to treatment, even after several courses of antidepressants. For people who have spent years searching for effective therapy, researchers are exploring fundamentally new approaches. One is psychedelic drugs, which may rapidly affect depression symptoms.

A new study, published in JAMA on October 26, 2026, reported encouraging results: after a single dose of the experimental nasal medication BPL-003, improvement was observed as soon as the next day, and its advantage over the control dose persisted for eight weeks.

About one-third of participants who received therapeutic doses showed a significant response to treatment. The psychedelic effects themselves, however, were much shorter than the potential therapeutic effects. These are results from a Phase 2 clinical trial and require further confirmation. The medication was administered in a clinical setting under specialist supervision and with psychological support.

What medication was tested, and who received it

BPL-003 contains synthetic mebufotenin, also known as 5-MeO-DMT. It is a serotonergic psychedelic: its effects are linked to serotonin receptors in the brain. Although the substance occurs in nature, the medication under study uses a synthetic form, not venom collected from toads.

Serotonin receptors are involved in regulating mood, perception, and other mental processes. However, interacting with these receptors alone does not explain why a brief exposure may be accompanied by relief from depression for weeks. The trial examined the clinical effect, while the precise mechanism behind its duration remains a subject of research.

Thirty-eight centers in Australia, Europe, and the United States took part in the randomized, double-blind trial. The primary analysis included 193 people aged 18 to 75. In their current depressive episode, they had not benefited from two to five courses of antidepressants. This treatment history distinguishes the group studied from people experiencing depression for the first time. Five neuroprofiles of depression were explored in the article.

Participants received a single dose of 8 mg, 12 mg, or a control dose of 0.3 mg. The low dose of the same substance made it possible to compare results within a similar procedure. BPL-003 was not directly compared in this study with conventional antidepressants, esketamine, or electroconvulsive therapy.

How quickly relief began and how long it lasted

Symptoms were assessed using the Montgomery–Åsberg Depression Rating Scale, or MADRS. It helps clinicians measure the severity of depression: the higher the score, the more severe the symptoms. The therapeutic doses showed an advantage over the control dose on day two–that is, the day after administration–and this persisted at subsequent assessments through day 57.

The primary prespecified outcome was assessed at about four weeks. On day 29, the reduction in depression severity in the 12 mg group was, on average, 5.3 points greater than in the control group. This is a difference between the groups’ average scores: individuals may have experienced much greater relief, a modest improvement, or no response to treatment.

To understand the results at the patient level, it is more useful to look at response and remission rates. Response means a reduction of at least half in the initial depression score. Remission means that the remaining symptoms have become sufficiently mild according to the criterion used in the study.

Single dose

Response at four weeks

Remission at four weeks

8 mg

35%

26%

12 mg

34%

18%

0.3 mg, control

12%

8%

In other words, significant improvement occurred in about one in three participants in the therapeutic-dose groups, compared with about one in eight in the control group. Remission was less common. These results show both the potential of the approach and its limitations: for most participants, a single session was not enough to produce a significant response.

An eight-week advantage in average scores does not mean that every patient remained in remission for eight weeks. The study also does not establish how reliably the medication prevents future relapses.

What the nasal formulation could change about treatment

Interest in BPL-003 stems from the combination of a short period of acute psychedelic effects with a longer-lasting change in symptoms. If the results are confirmed, treatment may be possible in relatively compact clinical sessions. For patients and healthcare services, the duration of monitoring matters in practical terms: it affects the demands on staff, the number of sessions that can be offered, and how care is organized.

After two hours, 85% of participants in the 8 mg group and 78% in the 12 mg group met the criteria for discharge. However, the protocol did not allow discharge until at least four hours after administration. It would therefore be inaccurate to describe the tested procedure as a two-hour session.

The spray was administered by a trained clinician, and treatment included psychological support. Nasal administration does not make a psychedelic suitable for unsupervised use at home. It changes how the substance is delivered, but does not remove the need to monitor a person during the acute effects.

What risks and questions remain

Adverse events after administration were recorded in 76% of participants in the 8 mg group, 85% in the 12 mg group, and 73% in the control group. The vast majority of reported events were mild or moderate. However, one participant who received 12 mg experienced two severe panic attacks that were considered related to treatment.

There is also a limitation common to psychedelic trials: noticeable changes in perception can allow participants and clinicians to guess which dose was assigned. This unblinding may amplify the influence of expectations on symptom assessments. The separate contribution of psychological support was not tested in this trial.

The study was funded by Beckley Psytech; the sponsor’s employees participated in the study design, analysis, and preparation of the publication. Confirmation in Phase 3 is needed to further assess efficacy and safety. Publication in a journal does not, by itself, mean regulatory approval: BPL-003 remains an investigational medication.

For someone with treatment-resistant depression, this study broadens the picture of possible future care options. The practical value of this approach will depend not only on rapid relief, but also on whether that relief can be sustained safely over the long term.

Can BPL-003 be used alongside conventional antidepressants?

This trial does not support recommending this combination. Antidepressants were discontinued under medical supervision before the medication was administered. Do not stop prescribed treatment on your own to pursue psychedelic therapy.

Can the medication be administered again if symptoms return?

This study did not establish the optimal schedule for repeat administration. It assessed a single dose, so the results cannot be applied to regular use: separate evidence on efficacy and safety would be needed.

Are BPL-003 and nasal esketamine the same medication?

No. They are different active substances with different mechanisms of action. The fact that both are administered nasally does not make them interchangeable. The BPL-003 trial also does not prove that it is superior to esketamine.

How was this article?

 

Share

Explore more